| Literature DB >> 28094303 |
Junlong Zhang1, Wenli Zhan1, Bin Yang1, Anning Tian1, Lin Chen1, Yun Liao1, Yongkang Wu1, Bei Cai1, Lanlan Wang1.
Abstract
Although the SLE risk gene loci of HLA-DR and HLA-DQ within the major histocompatibility complex (MHC) region has been gradually revealed by recent Genome-Wide Association studies (GWAS), the association of HLA-DP polymorphisms with SLE was minimally reported. Considering that the variants in rs3077 and rs9277535 in the HLA-DP region could influence the immune response by affecting antigen presentation of HLA class II molecules to CD4+ T cells, the present study aimed to explore the role of HLA-DP polymorphisms in SLE. In total, samples from 335 SLE patients and 635 healthy controls were collected and genotyped by a polymerase chain reaction-high resolution melting (PCR-HRM) assay. A significant positive correlation was observed between the SNP rs3077, rs9277535 of HLA-DP and SLE susceptibility (rs3077, OR = 0.74, 95%CI = 0.60-0.91, P = 0.004; rs9277535, OR = 0.72, 95%CI = 0.59-0.88, P = 0.001). Rs3077 polymorphism was corelated to IL-17, INF-γ and cutaneous vasculitis (P = 0.037, P = 0.020 and P = 0.006, respectively). Additionally, rs3077 AA genotype carriers showed lower concentration of inflammatory cytokines and lower cutaneous vasculitis incidence than did the other two genotype. No significant association was observed between rs9277535 and cytokines or any clinical features. In conclusion, HLA-DP polymorphisms (rs3077 and rs9277535) were associated with SLE susceptibility and the levels of some inflammatory cytokines in SLE patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28094303 PMCID: PMC5240340 DOI: 10.1038/srep39757
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The demographic and clinical characteristics of the subjects recruited in the study.
| Characteristics | SLE | Control | |
|---|---|---|---|
| Number of subjects | 335 | 635 | — |
| Age, mean ± SD (years) | 35.77 ± 13.25 | 36.28 ± 13.43 | 0.795 |
| Male (%)/Female (%) | 37 (11.04)/298 (88.96) | 80 (12.60)/555(87.40) | 0.480 |
| Disease duration, mean ± quartile interval (months) | 36.00 (12.00–96.00) | — | — |
| SLEDAI scores, mean ± SD | 11.76 ± 5.53 | — | — |
| ANA-positive(%) | 308 (91.94) | — | — |
| anti-dsDNA-positive (%) | 120 (35.82) | — | — |
| anti-Sm-positive(%) | 96 (28.66) | — | — |
| C3, mean ± SD(g/L) | 0.67 ± 0.30 | — | — |
| C4, mean ± SD(g/L) | 0.15 ± 0.08 | — | — |
| Cutaneous vasculitis (%) | 32 (9.55) | — | — |
| Arthritis (%) | 132 (39.40) | — | — |
| Albuminuria (%) | 250 (74.63) | — | — |
| Rash (%) | 100 (29.85) | — | — |
| Pleuritis (%) | 5 (1.49) | — | — |
| Pericarditis (%) | 5 (1.49) | — | — |
| Neurological disorder (%) | 33 (9.85) | — | — |
Abbreviations: SLE, systemic lupus erythematosus; SD, standard deviation; SLEDAI, SLE disease activity index; ANA, antinuclear antibody; anti-dsDNA, double-stranded DNA antibody; anti-Sm, Smith antibody; C3, complement 3; C4, complement 4.
Figure 1Linkage disequilibrium for two SNPs of HLA-DP in 970 individuals.
The linkage disequilibrium plot shows r2 values between rs3077 and rs9277535. There was not strong LD between rs3077 and rs9277535. D’ = 0.410, r2 = 0.130.
Genotype distributions of HLA-DP in SLE patients and controls in Chinese Han population.
| SNPs | Model | Genotype | SLE (n = 335) | Controls (n = 635) | OR(95%CI) | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | |||||
| rs3077 | GG | 182 | 54.33 | 276 | 43.46 | 1 | — | |
| GA | 128 | 38.21 | 301 | 47.40 | 0.65(0.49–0.85) | |||
| AA | 25 | 7.46 | 58 | 9.13 | 0.65(0.39–1.08) | 0.094 | ||
| Dominant | GA + AA/GG | — | — | — | — | 0.65(0.50–0.84) | ||
| Allele | G | 492 | 73.43 | 853 | 67.17 | 1 | — | |
| A | 178 | 26.57 | 417 | 32.83 | 0.74(0.60–0.91) | |||
| rs9277535 | GG | 166 | 49.55 | 231 | 36.38 | 1 | — | |
| GA | 127 | 37.91 | 314 | 49.45 | 0.56(0.42–0.75) | |||
| AA | 42 | 12.54 | 90 | 14.17 | 0.64(0.42–0.98) | |||
| Dominant | GA + AA/GG | — | — | — | — | 0.58(0.44–0.76) | ||
| Allele | G | 459 | 68.51 | 776 | 61.10 | 1 | — | |
| A | 211 | 31.49 | 494 | 38.90 | 0.72(0.59–0.88) | |||
Abbreviations: SLE, systemic lupus erythematosus; OR, odds ratio; CI, confidence interval.
Association between HLA-DP polymorphisms with serum cytokine characteristics in SLE patients.
| SNPs | Genotype | C3 | C4 | IFN-γ | IL-1β | IL-17 | IL-6 | IL-10 | TNF-α | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD(g/L) | Mean ± SD(g/L) | Mean ± SD(pg/ml) | Mean ± SD(pg/ml) | Mean ± quartile interval (pg/ml) | Mean ± quartile interval (pg/ml) | Mean ± quartile interval (pg/ml) | Mean ± quartile interval (pg/ml) | ||||||||||
| rs3077 | GG | 0.63 ± 0.27 | 0.14 ± 0.07 | 512.49 ± 199.16 | 4.07 ± 3.08 | 117.07(79.65–134.19) | 28.53(21.23–40.80) | 5.67(4.39–7.86) | 4.45(1.60–9.72) | ||||||||
| GA | 0.74 ± 0.33 | 0.16 ± 0.09 | 0.118 | 551.27 ± 193.35 | 4.75 ± 3.06 | 0.164 | 106.05(78.06–167.36) | 29.71(21.42–44.58) | 0.685 | 5.67(4.39–6.98) | 0.887 | 4.83(1.65–9.04) | 0.923 | ||||
| AA | 0.58 ± 0.29 | 0.13 ± 0.06 | 359.27 ± 203.34 | 2.82 ± 2.50 | 63.67(34.30–100.84) | 29.71(9.80–35.75) | 6.08(1.34–10.75) | 3.38(2.88–29.28) | |||||||||
| GG | 0.63 ± 0.27 | 0.14 ± 0.07 | 512.49 ± 199.16 | 4.07 ± 3.08 | 117.07(79.65–134.19) | 28.53(21.23–40.80) | 5.67(4.39–7.86) | 4.45(1.60–9.72) | |||||||||
| GA + AA | 0.71 ± 0.33 | 0.051 | 0.15 ± 0.09 | 0.830 | 509.03 ± 209.49 | 0.935 | 4.32 ± 3.03 | 0.693 | 100.83(64.75–157.17) | 0.488 | 29.71(19.29–42.00) | 0.871 | 5.77(4.39–7.22) | 0.674 | 4.38(2.16–9.19) | 0.929 | |
| AA | 0.58 ± 0.29 | 0.13 ± 0.06 | 359.27 ± 203.34 | 2.82 ± 2.50 | 63.67(34.30–100.84) | 29.71(9.80–35.75) | 6.08(1.34–10.75) | 3.38(2.88–29.28) | |||||||||
| GA + GG | 0.68 ± 0.30 | 0.748 | 0.15 ± 0.08 | 0.448 | 530.93 ± 196.18 | 4.39 ± 3.07 | 114.33(77.74–157.17) | 28.83(21.18–43.60) | 0.454 | 5.67(4.39–7.53) | 0.924 | 4.76(1.6–9.72) | 0.591 | ||||
| rs9277535 | GG | 0.66 ± 0.29 | 0.14 ± 0.07 | 519.99 ± 190.57 | 3.96 ± 2.58 | 110.24(76.79–127.48) | 26.19(20.55–39.60) | 6.38(4.61–7.47) | 4.4(1.44–9.74) | ||||||||
| GA | 0.66 ± 0.27 | 0.299 | 0.14 ± 0.07 | 0.060 | 508.42 ± 226.99 | 0.895 | 4.58 ± 3.58 | 0.569 | 106.05(63.67–165.86) | 0.949 | 48.34(34.36–103.58) | 0.806 | 5.93(5.57–7.66) | 0.633 | 4.76(3.11–21.07) | 0.824 | |
| AA | 0.73 ± 0.36 | 0.18 ± 0.12 | 489.50 ± 174.72 | 3.78 ± 2.50 | 104.17(77.42–132.41) | 32.08(18.42–42.79) | 5.87(4.39–9.00) | 4.16(2.05–7.38) | |||||||||
| GG | 0.66 ± 0.29 | 0.14 ± 0.07 | 519.99 ± 190.57 | 3.96 ± 2.58 | 110.24(76.79–127.48) | 26.19(20.55–39.60) | 6.38(4.61–7.47) | 4.4(1.44–9.74) | |||||||||
| GA + AA | 0.68 ± 0.31 | 0.698 | 0.15 ± 0.09 | 0.805 | 503.86 ± 214.16 | 0.708 | 4.39 ± 3.35 | 0.501 | 105.45(69.88–162.32) | 0.827 | 30.01(19.29–45.12) | 0.369 | 5.36(4.06–7.65) | 0.731 | 4.83(2.87–9.20) | 0.565 | |
| AA | 0.73 ± 0.36 | 0.18 ± 0.12 | 489.50 ± 174.72 | 3.78 ± 2.50 | 104.17(77.42–132.41) | 32.08(18.42–42.79) | 5.87(4.39–9.00) | 4.16(2.05–7.38) | |||||||||
| GA + GG | 0.66 ± 0.29 | 0.151 | 0.14 ± 0.07 | 514.06 ± 208.78 | 0.689 | 4.28 ± 3.13 | 0.587 | 107.81(67.85–142.21) | 0.881 | 28.83(19.72–40.38) | 0.599 | 5.67(4.28–7.62) | 0.735 | 4.45(1.99–9.74) | 0.925 |
Association between HLA-DP polymorphisms with clinical characteristics in SLE patients.
| Clinical feature | Rs3077 | Rs9277535 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotype frequency(n(%)) | χ2 | p-Value | Genotype frequency(n(%)) | χ2 | p-Value | |||||
| GG | GA | AA | GG | GA | AA | |||||
| Cutaneous vasculitis | 26(81.25) | 5(15.63) | 1(3.13) | 10.132 | 0.006 | 19(59.38) | 9(28.13) | 4(12.50) | 1.575 | 0.460 |
| Arthritis | 78(59.09) | 42(31.82) | 12(9.09) | 4.012 | 0.134 | 68(51.52) | 48(36.36) | 16(12.12) | 0.337 | 0.846 |
| Albuminuria | 141(56.40) | 89(35.60) | 20(8.00) | 2.915 | 0.241 | 126(50.40) | 97(38.80) | 27(10.80) | 2.721 | 0.263 |
| Rash | 58(58.00) | 34(34.00) | 8(8.00) | 1.070 | 0.614 | 50(50.00) | 39(39.00) | 11(11.00) | 0.319 | 0.865 |
| Pleuritis | 2(40.00) | 1(20.00) | 2(40.00) | 5.279 | 0.062 | 2(40.00) | 2(40.00) | 1(20.00) | 0.891 | 0.824 |
| Pericarditis | 2(40.00) | 1(20.00) | 2(40.00) | 5.279 | 0.062 | 2(40.00) | 2(40.00) | 1(20.00) | 0.891 | 0.824 |
| Neurological disorder | 16(48.48) | 13(39.39) | 4(12.12) | 1.565 | 0.423 | 11(33.33) | 16(48.48) | 6(18.18) | 4.225 | 0.113 |
aFisher’s exact test.
Distribution of the genotype and allele frequencies of rs3077 polymorphism in cutaneous vasculitis (CV) and non-CV patients.
| CV(n = 32),n(%) | Non-CV(303),n(%) | χ2 | p-Value | OR (95%CI) | ||
|---|---|---|---|---|---|---|
| Genotype | GG | 26(81.25) | 156(51.49) | 10.132 | NA | |
| GA | 5(15.63) | 123(40.59) | ||||
| AA | 1(3.13) | 24(7.92) | ||||
| Allele | G | 57(89.06) | 435(71.78) | 8.860 | — | |
| A | 7(10.94) | 171(28.22) | 0.312(0.140–0.699) | |||
| Dominant model | GG | 26(81.25) | 156(51.49) | 10.334 | — | |
| GA + AA | 6(18.75) | 147(48.51) | 0.245(0.098–0.612) | |||
| Recessive model | AA | 1(3.13) | 24(7.92) | 0.964 | 0.490 | — |
| GG + GA | 31(96.88) | 279(92.08) | 2.667(0.349–20.396) |
Abbreviations: CV: cutaneous vasculitis; OR, odds ratio; CI, confidence interval; NA: not available.